Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jianxin Lin

Showing results (81-90 of 86) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 86 results.
European Journal of Cancer (Oxford, England : 1990)|April 22, 2025
Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 studyMakoto Tahara, Richard Greil, Danny Rischin, et al.
JAMA Oncology|July 17, 2020
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical TrialsIgor Puzanov, Antoni Ribas, Caroline Robert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2022
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 StudyKevin J Harrington, Barbara Burtness, Richard Greil, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2024
Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non-small cell lung cancer, and renal cell carcinomaJason J Luke, Georgina V Long, Caroline Robert, et al.
The European Respiratory Journal|September 11, 2023
Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trialRogerio Souza, David B Badesch, H Ardeschir Ghofrani, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2020
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanomaCaroline Robert, Wen-Jen Hwu, Omid Hamid, et al.
Pageof 9

Showing results (81-90 of 86) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 86 results.
European Journal of Cancer (Oxford, England : 1990)|April 22, 2025
Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 studyMakoto Tahara, Richard Greil, Danny Rischin, et al.
JAMA Oncology|July 17, 2020
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical TrialsIgor Puzanov, Antoni Ribas, Caroline Robert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2022
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 StudyKevin J Harrington, Barbara Burtness, Richard Greil, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2024
Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non-small cell lung cancer, and renal cell carcinomaJason J Luke, Georgina V Long, Caroline Robert, et al.
The European Respiratory Journal|September 11, 2023
Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trialRogerio Souza, David B Badesch, H Ardeschir Ghofrani, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2020
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanomaCaroline Robert, Wen-Jen Hwu, Omid Hamid, et al.
Pageof 9